Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - μονοϋδρική προπανοδιόλη δαπαγλιφλοζίνης - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - Φάρμακα που χρησιμοποιούνται στον διαβήτη - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. σε συνδυασμό με άλλα φαρμακευτικά προϊόντα για τη θεραπεία του διαβήτη τύπου 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 και 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

astrazeneca ab - μονοϋδρική προπανοδιόλη δαπαγλιφλοζίνης - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - Φάρμακα που χρησιμοποιούνται στον διαβήτη - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. σε συνδυασμό με άλλα φαρμακευτικά προϊόντα για τη θεραπεία του διαβήτη τύπου 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 και 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - Φάρμακα που χρησιμοποιούνται στον διαβήτη - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 και 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

dapagliflozin - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 10mg/tab - dapagliflozin 10mg - dapagliflozin

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

dapagliflozin - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 5mg/tab - dapagliflozin 5mg - dapagliflozin

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

tad pharma gmbh (0000009356) heinz-lohmann-strasse 5, cuxhaven, d-27472 - dapagliflozin propanediol - film coated tablets - 5mg - dapagliflozin propanediol (0960404482) 6,15mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

tad pharma gmbh (0000009356) heinz-lohmann-strasse 5, cuxhaven, d-27472 - dapagliflozin propanediol - film coated tablets - 10mg - dapagliflozin propanediol (0960404482) 12,3mg